PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

Cagrilintide

Cagrilintide is a synthetic, long-acting amylin analogue. Modeled after the naturally occurring pancreatic hormone amylin, a potent agent for chronic weight management and glycemic control, often paired synergistically with GLP-1 receptor agonists.

1. Chemical Structure and Biochemistry

Cagrilintide is an acylated peptide, meaning its structure is modified with a fatty acid chain.

  • Structural Modification: The attachment of a fatty acid diacid moiety allows the peptide to bind tightly to serum albumin in the bloodstream. This prevents rapid renal clearance and enzymatic degradation, drastically extending its half-life to accommodate once-weekly dosing rather than daily administration.

2. Mechanism of Action

Cagrilintide acts as a non-selective agonist at both amylin and calcitonin receptors.

  • Satiety and Gastric Emptying: By mimicking amylin, it acts directly on the brain's satiety centers (such as the area postrema) to induce feelings of fullness. It also slows gastric emptying, thereby reducing meal-time blood glucose spikes.
  • Glucagon Suppression: It inhibits the postprandial secretion of glucagon, an endogenous hormone that raises blood sugar.

3. Research and Applications

Cagrilintide is at the forefront of advanced metabolic therapies.

  • Obesity and Weight Loss: Investigated as a standalone treatment for obesity and in combination therapies (e.g., CagriSema, a combination of Cagrilintide and Semaglutide) to achieve synergistic weight loss that rivals bariatric surgery in clinical trials.
  • Type 2 Diabetes: Studied for its ability to lower HbA1c levels without promoting weight gain or hypoglycemia.
Tags: Cagrilintide Cargilintide amylin-analogue acylated-peptide calcitonin-receptor-agonist obesity-research weight-loss-peptide CagriSema delayed-gastric-emptying